News
| 4 min read
In vivo CAR T, lab-grown eggs, trial access, postpartum depression, and RNA therapy for hereditary angioedema led drug discovery this week.
| 2 min read
Qfitlia, an RNAi therapeutic given every two months, is the first to target the antithrombin protein instead of missing clotting factors in the blood.
| 3 min read
By combining synthetic biology, computational design, and novel RNA formats, these therapies adapt in real time to disease signals, enabling previously impossible treatments.
| 3 min read
After decades of stalled innovation, a new oral antibiotic could now combat both everyday infections and urgent public health threats.
| 2 min read
First DPP1 inhibitor drug milestone marks a long-awaited breakthrough for NCFB patients.
| 4 min read
Sepsis antibody breakthroughs, a billion-dollar KRAS deal, and FDA’s push to rebuild domestic drug manufacturing led the drug discovery news this week.
| 2 min read
Industry experts and consulting firms warn that proposed import tariffs could drive up drug prices, disrupt global supply chains, and divert investment away from critical R&D pipelines.
| 2 min read
As the FDA begins AI-assisted regulatory review, the industry ponders how to best tailor their submissions.
| 3 min read
COPD breakthroughs, billion-dollar biotech bets, brain-computer trials, and a historic push for women’s health led the news this week.
| 2 min read
New data suggests icotrokinra could challenge injectables with once-daily targeted peptide.
| 5 min read
Advances in screening and protein targeting are reviving interest in molecular glues as a strategy to tackle previously undruggable diseases.
| 3 min read
The deal reflects growing interest in covalent chemistry as a solution for “undruggable” inflammatory proteins.
